Trials / Terminated
TerminatedNCT00408473
Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.
A Randomised Double-blind Pilot Study Comparing Flecainide CR and Placebo in the Early Treatment of Patients With a Documented First Episode of Atrial Fibrillation.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 256 (planned)
- Sponsor
- MEDA Pharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flecainide |
Timeline
- First posted
- 2006-12-07
- Last updated
- 2022-02-07
Locations
47 sites across 7 countries: Belgium, Bulgaria, France, Germany, Netherlands, Romania, Spain
Source: ClinicalTrials.gov record NCT00408473. Inclusion in this directory is not an endorsement.